JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buisson, M.
Right arrow Articles by Seigneurin, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buisson, M.
Right arrow Articles by Seigneurin, J. M.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 1999, p. 2709-2714, Vol. 37, No. 8
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Novel Immunoblot Assay Using Four Recombinant Antigens for Diagnosis of Epstein-Barr Virus Primary Infection and Reactivation

M. Buisson,1,* B. Fleurent,2 M. Mak,3 P. Morand,1 L. Chan,4 A. Ng,3 M. Guan,3 D. Chin,3 and J. M. Seigneurin1

Laboratoire de Virologie Médicale Moléculaire, RHAP-CNRS, Faculté de Médecine, 38043 Grenoble, France1; Genelabs Diagnostics S.A., Geneva, Switzerland2; and Genelabs Diagnostics Pte. Ltd.,3 and Bioprocessing Technology Center, National University of Singapore,4 Singapore, Republic of Singapore

Received 28 September 1998/Returned for modification 20 January 1999/Accepted 22 April 1999

A new immunoblot assay, composed of four Epstein-Barr virus (EBV)-encoded recombinant proteins (virus capsid antigen [VCA] p23, early antigen [EA] p138, EA p54, and EBNA-1 p72), was compared with an immunofluorescence assay on a total of 291 sera. The test was accurate in 94.5% of cases of primary EBV infection, while an immunoglobulin G anti-VCA p23 band with strong intensity correlated with reactivation.

* Corresponding author. Mailing address: Laboratoire de Virologie, CHU/Faculté de médecine, BP 217, 38043 Grenoble, France. Phone: 334 76 76 56 04. Fax: 334 76 76 52 28. E-mail: Marlyse.Buisson{at}ujf-grenoble.fr.

Journal of Clinical Microbiology, August 1999, p. 2709-2714, Vol. 37, No. 8
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 1999 by the American Society for Microbiology. All rights reserved.